共 121 条
[1]
Boulle A(2008)Outcomes of nevirapine and efavirenz based antiretroviral therapy when co-administered with rifampicin based anti tubercular therapy JAMA. 300 530-539
[2]
Van Cutsem G(2001)Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected Patients AIDS 15 71-5
[3]
Cohen K(2009)Safety and efficacy of nevirapine and efavirenz based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana Int J Tuberc Lung Dis. 13 360-6
[4]
Hilderbrand K(2007)Liver toxicity induced by non nucleoside reverse transcriptase inhibitors J Antimicrob Chemother 59 342-6
[5]
Mathee S(2004)Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study AIDS 18 2391-400
[6]
Abrahams M(2010)Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation Drug Metab Dispos. 38 1218-1229
[7]
Goemaere E(2010)Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults AIDS Res Ther 26 7-8
[8]
Coetzee D(2009)Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine Drug Metab Dispos. 37 1793-1796
[9]
Maartens G(2008)High prevalence of the CYP2B6 516 G → T (*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe Eur J Clin Pharmacol 64 357-365
[10]
Marzolini C(2001)Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics. 11 399-415